TY - CHAP M1 - Book, Section TI - Multiple Myeloma and Other Plasma Cell Dyscrasias A1 - Lee, Hans C. A1 - Patel, Krina A1 - Kongtim, Piyanuch A1 - Parmar, Simrit A1 - Lin, Pei A1 - Qazilbash, Muzaffar H. A1 - Thomas, Sheeba A1 - Manasanch, Elisabet E. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. PY - 2016 T2 - The MD Anderson Manual of Medical Oncology, 3e AB - Plasma cell dyscrasias are heterogeneous disorders arising from the proliferation of a monoclonal population of plasma cells. Some of these disorders can present serendipitously as benign processes that can be observed; others are highly aggressive and require immediate intervention. The most common plasma cell dyscrasia is monoclonal gammopathy of undetermined significance (MGUS), a benign condition that can be observed. Related disorders include smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma of the bone, extramedullary plasmacytoma, Waldenström macroglobulinemia (WM), primary amyloid light-chain (AL) amyloidosis, heavy-chain disease, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, and the recently recognized TEMPI (telangiectasias, elevated erythropoietin and erythrocytosis, monoclonal gammopathy, perinephric fluid collection, and intrapulmonary shunting) syndrome. The spectrum of MGUS, SMM, and MM represents a natural progression of the same disease. This chapter focuses on the etiology, genetics, biology, diagnosis, clinical features, and current therapy of MM and other plasma cell disorders. SN - PB - McGraw-Hill Medical CY - New York, NY Y2 - 2024/10/13 UR - hemonc.mhmedical.com/content.aspx?aid=1126741074 ER -